Program
stapokibart
Also written as “CM310”, “Stapokibart” and “Stapokibart injection”.
Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Nasal Polyps · Asthma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 246 open or running | phase 3since Feb 17, 2022 | Mar 12, 2021 | Feb 2027phase 3 · NCT07106372 |
| Chengdu Kangnuoxing Biopharma,Inc. | 33 open or running | phase 3since Sep 30, 2025 | Sep 30, 2025 | Dec 2026phase 3 · NCT07678931 |
| CSPC Pharmaceutical Group | 22 open or running | phase 3since Feb 27, 2023 | Feb 27, 2023 | Apr 29, 2032phase 3 · NCT06547333 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Mar 12, 2021.
- Nov 29, 2023Phase 2 study in Dermatitis, AtopicKeymed Biosciences · NCT06162507 · 24 enrolled · China
- Nov 29, 2023Phase 1 study in HealthyKeymed Biosciences · NCT06161090 · 33 enrolled · China
- Dec 4, 2023Phase 2 study in Rhinitis, Allergic, SeasonalKeymed Biosciences · NCT06171074 · 100 planned · China
- Dec 5, 2023Phase 1 study in HealthyKeymed Biosciences · NCT06171048 · 236 planned · China
- Feb 18, 2024Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06277765 · 180 enrolled · China
- May 16, 2024Phase 3 study in Prurigo NodularisKeymed Biosciences · NCT06424470 · 200 enrolled · China
- Jul 2, 2024Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06495229 · 180 enrolled · China
- Jul 24, 2024Phase 2 study in Rhinitis, AllergicKeymed Biosciences · NCT06525597 · 120 planned · China
- Aug 7, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT06547333 · 884 planned
- Apr 30, 2025Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06956196 · 240 planned · China
- Aug 5, 2025Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT07106372 · 240 planned · China
- Sep 30, 2025Chengdu Kangnuoxing Biopharma,Inc.'s first study: phase 3 study in Pemphigoid, BullousNew to Chengdu Kangnuoxing Biopharma,Inc.Chengdu Kangnuoxing Biopharma,Inc. · NCT07210554 · 200 planned · China
- May 21, 2026Phase 2 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07617324 · 15 planned · China
- Jun 25, 2026Phase 3 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07678931 · 136 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07678931
- Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT07106372
- Mar 27, 2028Primary completion: phase 3 study in Pemphigoid, BullousChengdu Kangnuoxing Biopharma,Inc. · NCT07210554
- Apr 29, 2032Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT06547333
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07678931Rhinitis, Allergic, Seasonal · China | 3 | Recruiting | Chengdu Kangnuoxing Biopharma,Inc. | Dec 2026 | 136 |
| NCT07617324Rhinitis, Allergic, Seasonal · China | 2 | Not yet recruiting | Chengdu Kangnuoxing Biopharma,Inc. | Oct 2026 | 15 |
| NCT07210554Pemphigoid, Bullous · China | 3 | Not yet recruiting | Chengdu Kangnuoxing Biopharma,Inc. | Mar 27, 2028 | 200 |
| NCT07106372Dermatitis, Atopic · China | 3 | Not yet recruiting | Keymed Biosciences | Feb 2027 | 240 |
| NCT06956196Dermatitis, Atopic · China | 3 | Not yet recruiting | Keymed Biosciences | May 2026 | 240 |
| NCT06547333Pulmonary Disease, Chronic Obstructive | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 29, 2032 | 884 |
| NCT06525597Rhinitis, Allergic · China | 2 | Recruiting | Keymed Biosciences | Oct 30, 2025 | 120 |
| NCT06495229Dermatitis, Atopic · China | 3 | Active, not recruiting | Keymed Biosciences | Aug 30, 2026 | 180 |
| NCT06424470Prurigo Nodularis · China | 3 | Completed | Keymed Biosciences | Feb 11, 2026 | 200 |
| NCT06277765Dermatitis, Atopic · China | 3 | Completed | Keymed Biosciences | Jan 23, 2025 | 180 |
| NCT06171048Healthy · China | 1 | Not yet recruiting | Keymed Biosciences | Apr 30, 2025 | 236 |
| NCT06171074Rhinitis, Allergic, Seasonal · China | 2 | Not yet recruiting | Keymed Biosciences | Mar 30, 2025 | 100 |
| NCT06162507Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Jul 4, 2024 | 24 |
| NCT06161090Healthy · China | 1 | Completed | Keymed Biosciences | Jan 13, 2020 | 33 |
| NCT06116565Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Nov 26, 2025 | 263 |
| NCT05908721Rhinitis, Allergic · China | 2 | Completed | Keymed Biosciences | Dec 10, 2023 | 100 |
| NCT05908032Rhinitis, Allergic · China | 3 | Completed | Keymed Biosciences | Dec 4, 2023 | 108 |
| NCT05761028Moderate to Severe Asthma · China | 3 | Recruiting | CSPC Pharmaceutical Group | May 2032 | 600 |
| NCT05715320Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Jul 18, 2024 | 160 |
| NCT05702450Healthy · China | 1 | Completed | Keymed Biosciences | Jul 26, 2023 | 240 |
| NCT05579925Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Jul 28, 2023 | 24 |
| NCT05452343Chronic Pruritus of Unknown Origin | 2 | UNKNOWN | Keymed Biosciences | Mar 1, 2024 | 50 |
| NCT05265923Dermatitis, Atopic · China | 3 | Completed | Keymed Biosciences | Oct 31, 2023 | 500 |
| NCT05186909Asthma · China | 2 | Completed | Keymed Biosciences | Sep 13, 2023 | 52 |
| NCT05131464Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Completed | Keymed Biosciences | Jan 31, 2024 | 46 |
| NCT04893707Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Feb 3, 2023 | 127 |
| NCT04893941Moderate-to-severe Atopic Dermatitis · China | 2 | Completed | Keymed Biosciences | Jan 22, 2021 | 39 |
| NCT04805411Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Nov 8, 2021 | 120 |
| NCT04805398Disease · China | 2 | Completed | Keymed Biosciences | Mar 18, 2022 | 56 |
How it is read
Names in the registry
- “CM310”, 22 entries
- “Stapokibart”, 2 entries
- “Stapokibart injection”, 2 entries
- “Stapokibatrt”, 2 entries
- “Stapokibart Injection”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 12 studies
- Rhinitis, Allergic, Seasonal, 3 studies
- Rhinitis, Allergic, 3 studies
- Nasal Polyps, 2 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.